Skip to main content
Erschienen in: Pathology & Oncology Research 4/2018

26.08.2017 | Original Article

Intratumoral Heterogeneity of Somatic Mutations for NRIP1, DOK1, ULK1, ULK2, DLGAP3, PARD3 and PRKCI in Colon Cancers

verfasst von: Eun Ji Choi, Ju Hwa Lee, Min Sung Kim, Sang Yong Song, Nam Jin Yoo, Sug Hyung Lee

Erschienen in: Pathology & Oncology Research | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Abstract

Both NRIP1 and DOK1 genes are considered candidate tumor suppressor genes (TSGs). Also, cell polarity-related genes PARD3, PRKCI and DLGAP3, and autophagy-related genes ULK1 and ULK2 genes are considered to play crucial roles in tumorigenesis. The aim of our study was to find whether these genes were mutated in colorectal cancer (CRC). In a genome database, we observed that each of these genes harbored mononucleotide repeats in the coding sequences, which could be mutated in cancers with high microsatellite instability (MSI-H). For this, we studied 124 CRCs for the frameshift mutations of these genes and their intratumoral heterogeneity (ITH). NRIP1, DOK1, PARD3, PRKCI, DLGAP3, ULK1 and ULK2 harbored 18 (22.8%), 2 (2.5%), 2 (2.5%), 2 (2.5%), 5 (6.3%), 2 (2.5%) and 2 (2.5%) of 79 CRCs with MSI-H, respectively. However, we found no such mutations in microsatellite stable (MSS) cancers in the nucleotide repeats. We also studied ITH for the frameshift mutations in 16 cases of CRCs and detected that the frameshift mutations of NRIP1, DOK1, PARD3, PRKCI, DLGAP3, ULK1 and ULK2 showed regional ITH in 5 (31.3%), 2 (12.5%), 0 (0%), 0 (0%), 1 (6.3%), 1 (6.3%) and 3 (18.8%) cases, respectively. Our data exhibit that candidate cancer-related genes NRIP1, DOK1, PARD3, PRKCI, DLGAP3, ULK1 and ULK2 harbor mutational ITH as well as the frameshift mutations in CRC with MSI-H. Also, the results suggest that frameshift mutations of these genes might play a role in tumorigenesis through their inactivation in CRC.
Literatur
1.
Zurück zum Zitat Docquier A, Harmand PO, Fritsch S, Chanrion M, Darbon JM, Cavaillès V (2010) The transcriptional coregulator RIP140 represses E2F1 activity and discriminates breast cancer subtypes. Clin Cancer Res 16:2959–2970CrossRefPubMedPubMedCentral Docquier A, Harmand PO, Fritsch S, Chanrion M, Darbon JM, Cavaillès V (2010) The transcriptional coregulator RIP140 represses E2F1 activity and discriminates breast cancer subtypes. Clin Cancer Res 16:2959–2970CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Lapierre M, Bonnet S, Bascoul-Mollevi C, Ait-Arsa I, Jalaguier S, Del Rio M, Plateroti M, Roepman P, Ychou M, Pannequin J, Hollande F, Parker M, Cavailles V (2014) RIP140 increases APC expression and controls intestinal homeostasis and tumorigenesis. J Clin Invest 124:1899–1913CrossRefPubMedPubMedCentral Lapierre M, Bonnet S, Bascoul-Mollevi C, Ait-Arsa I, Jalaguier S, Del Rio M, Plateroti M, Roepman P, Ychou M, Pannequin J, Hollande F, Parker M, Cavailles V (2014) RIP140 increases APC expression and controls intestinal homeostasis and tumorigenesis. J Clin Invest 124:1899–1913CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Di Cristofano A, Carpino N, Dunant N, Friedland G, Kobayashi R, Strife A, Wisniewski D, Clarkson B, Pandolfi PP, Resh MD (1998) Molecular cloning and characterization of p56dok-2 defines a new family of RasGAP-binding proteins. J Biol Chem 273:4827–4830CrossRefPubMed Di Cristofano A, Carpino N, Dunant N, Friedland G, Kobayashi R, Strife A, Wisniewski D, Clarkson B, Pandolfi PP, Resh MD (1998) Molecular cloning and characterization of p56dok-2 defines a new family of RasGAP-binding proteins. J Biol Chem 273:4827–4830CrossRefPubMed
4.
Zurück zum Zitat Berger AH, Niki M, Morotti A, Taylor BS, Socci ND, Viale A, Brennan C, Szoke J, Motoi N, Rothman PB, Teruya-Feldstein J, Gerald WL, Ladanyi M, Pandolfi PP (2010) Identification of DOK genes as lung tumor suppressors. Nat Genet 42:216–223CrossRefPubMedPubMedCentral Berger AH, Niki M, Morotti A, Taylor BS, Socci ND, Viale A, Brennan C, Szoke J, Motoi N, Rothman PB, Teruya-Feldstein J, Gerald WL, Ladanyi M, Pandolfi PP (2010) Identification of DOK genes as lung tumor suppressors. Nat Genet 42:216–223CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Zen K, Yasui K, Gen Y, Dohi O, Wakabayashi N, Mitsufuji S, Itoh Y, Zen Y, Nakanuma Y, Taniwaki M, Okanoue T, Yoshikawa T (2009) Defective expression of polarity protein PAR-3 gene (PARD3) in esophageal squamous cell carcinoma. Oncogene 28:2910–2918CrossRefPubMed Zen K, Yasui K, Gen Y, Dohi O, Wakabayashi N, Mitsufuji S, Itoh Y, Zen Y, Nakanuma Y, Taniwaki M, Okanoue T, Yoshikawa T (2009) Defective expression of polarity protein PAR-3 gene (PARD3) in esophageal squamous cell carcinoma. Oncogene 28:2910–2918CrossRefPubMed
6.
Zurück zum Zitat Suzuki A, Yamanaka T, Hirose T, Manabe N, Mizuno K, Shimizu M, Akimoto K, Izumi Y, Ohnishi T, Ohno S (2001) Atypical protein kinase C is involved in the evolutionarily conserved par protein complex and plays a critical role in establishing epithelia-specific junctional structures. J Cell Biol 152:1183–1196CrossRefPubMedPubMedCentral Suzuki A, Yamanaka T, Hirose T, Manabe N, Mizuno K, Shimizu M, Akimoto K, Izumi Y, Ohnishi T, Ohno S (2001) Atypical protein kinase C is involved in the evolutionarily conserved par protein complex and plays a critical role in establishing epithelia-specific junctional structures. J Cell Biol 152:1183–1196CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Mazzarella R, Ciccodicola A, Esposito T, Arcucci A, Migliaccio C, Jones C, Schlessinger D, D'Urso M, D'Esposito M (1995) Human protein kinase C iota gene (PRKCI) is closely linked to the BTK gene in Xq21.3. Genomics 26:629–631CrossRefPubMed Mazzarella R, Ciccodicola A, Esposito T, Arcucci A, Migliaccio C, Jones C, Schlessinger D, D'Urso M, D'Esposito M (1995) Human protein kinase C iota gene (PRKCI) is closely linked to the BTK gene in Xq21.3. Genomics 26:629–631CrossRefPubMed
8.
Zurück zum Zitat Ebnet K, Suzuki A, Horikoshi Y, Hirose T, Meyer Zu Brickwedde MK, Ohno S, Vestweber D (2001) The cell polarity protein ASIP/PAR-3 directly associates with junctional adhesion molecule (JAM). EMBO J 20:3738–3748CrossRefPubMedPubMedCentral Ebnet K, Suzuki A, Horikoshi Y, Hirose T, Meyer Zu Brickwedde MK, Ohno S, Vestweber D (2001) The cell polarity protein ASIP/PAR-3 directly associates with junctional adhesion molecule (JAM). EMBO J 20:3738–3748CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Welch JM, Wang D, Feng G (2004) Differential mRNA expression and protein localization of the SAP90/PSD-95-associated proteins (SAPAPs) in the nervous system of the mouse. J Comp Neurol 472:24–39CrossRefPubMed Welch JM, Wang D, Feng G (2004) Differential mRNA expression and protein localization of the SAP90/PSD-95-associated proteins (SAPAPs) in the nervous system of the mouse. J Comp Neurol 472:24–39CrossRefPubMed
11.
Zurück zum Zitat Imai K, Yamamoto H (2008) Carcinogenesis and microsatellite instability: the interrelationship between genetics and epigenetics. Carcinogenesis 29:673–680CrossRefPubMed Imai K, Yamamoto H (2008) Carcinogenesis and microsatellite instability: the interrelationship between genetics and epigenetics. Carcinogenesis 29:673–680CrossRefPubMed
12.
Zurück zum Zitat Marusyk A, Almendro V, Polyak K (2012) Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer 12:323–334CrossRefPubMed Marusyk A, Almendro V, Polyak K (2012) Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer 12:323–334CrossRefPubMed
13.
Zurück zum Zitat McGranahan N, Swanton C (2015) Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. Cancer Cell 27:15–26CrossRefPubMed McGranahan N, Swanton C (2015) Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. Cancer Cell 27:15–26CrossRefPubMed
14.
Zurück zum Zitat Choi YJ, Rhee JK, Hur SY, Kim MS, Lee SH, Chung YJ, Kim TM, Lee SH (2017) Intraindividual genomic heterogeneity of high-grade serous carcinoma of the ovary and clinical utility of ascitic cancer cells for mutation profiling. J Pathol 241:57–66CrossRefPubMed Choi YJ, Rhee JK, Hur SY, Kim MS, Lee SH, Chung YJ, Kim TM, Lee SH (2017) Intraindividual genomic heterogeneity of high-grade serous carcinoma of the ovary and clinical utility of ascitic cancer cells for mutation profiling. J Pathol 241:57–66CrossRefPubMed
15.
Zurück zum Zitat Murphy K, Zhang S, Geiger T, Hafez MJ, Bacher J, Berg KD, Eshleman JR (2006) Comparison of the microsatellite instability analysis system and the Bethesda panel for the determination of microsatellite instability in colorectal cancers. J Mol Diagn 8:305–311CrossRefPubMedPubMedCentral Murphy K, Zhang S, Geiger T, Hafez MJ, Bacher J, Berg KD, Eshleman JR (2006) Comparison of the microsatellite instability analysis system and the Bethesda panel for the determination of microsatellite instability in colorectal cancers. J Mol Diagn 8:305–311CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Jung SH, Kim MS, Jung CK, Park HC, Choi HJ, Maeng L, Min KO, Kim J, Park TI, Shin OR, Kim TJ, Xu H, Lee KY, Kim TM, Song SY, Lee C, Chung YJ, Lee SH (2016) Whole-exome sequencing identifies recurrent AKT1 mutations in sclerosing hemangioma of lung. Proc Natl Acad Sci U S A 113:10672–10677CrossRefPubMedPubMedCentral Jung SH, Kim MS, Jung CK, Park HC, Choi HJ, Maeng L, Min KO, Kim J, Park TI, Shin OR, Kim TJ, Xu H, Lee KY, Kim TM, Song SY, Lee C, Chung YJ, Lee SH (2016) Whole-exome sequencing identifies recurrent AKT1 mutations in sclerosing hemangioma of lung. Proc Natl Acad Sci U S A 113:10672–10677CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Jo YS, Choi MR, Song SY, Kim MS, Yoo NJ, Lee SH (2016) Frameshift mutations of HSPA4 and MED13 in gastric and colorectal cancers. Pathol Oncol Res 22:769–772CrossRefPubMed Jo YS, Choi MR, Song SY, Kim MS, Yoo NJ, Lee SH (2016) Frameshift mutations of HSPA4 and MED13 in gastric and colorectal cancers. Pathol Oncol Res 22:769–772CrossRefPubMed
18.
Zurück zum Zitat Choi EJ, Kim MS, Song SY, Yoo NJ, Lee SH (2017) Intratumoral heterogeneity of frameshift mutations in MECOM gene is frequent in colorectal cancers with high microsatellite instability. Pathol Oncol Res 23:145–149CrossRefPubMed Choi EJ, Kim MS, Song SY, Yoo NJ, Lee SH (2017) Intratumoral heterogeneity of frameshift mutations in MECOM gene is frequent in colorectal cancers with high microsatellite instability. Pathol Oncol Res 23:145–149CrossRefPubMed
19.
Zurück zum Zitat Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Nature Reviews Cell 144:646–674 Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Nature Reviews Cell 144:646–674
20.
Zurück zum Zitat Calin GA, Gafà R, Tibiletti MG, Herlea V, Becheanu G, Cavazzini L, Barbanti-Brodano G, Nenci I, Negrini M, Lanza G (2000) Genetic progression in microsatellite instability high (MSI-H) colon cancers correlates with clinico-pathological parameters: a study of the TGRbetaRII, BAX, hMSH3, hMSH6, IGFIIR and BLM genes. Int J Cancer 89:230–235CrossRefPubMed Calin GA, Gafà R, Tibiletti MG, Herlea V, Becheanu G, Cavazzini L, Barbanti-Brodano G, Nenci I, Negrini M, Lanza G (2000) Genetic progression in microsatellite instability high (MSI-H) colon cancers correlates with clinico-pathological parameters: a study of the TGRbetaRII, BAX, hMSH3, hMSH6, IGFIIR and BLM genes. Int J Cancer 89:230–235CrossRefPubMed
21.
Zurück zum Zitat Choi YJ, Kim MS, An CH, Yoo NJ, Lee SH (2014) Regional bias of intratumoral genetic heterogeneity of nucleotide repeats in colon cancers with microsatellite instability. Pathol Oncol Res 20:965–971CrossRefPubMed Choi YJ, Kim MS, An CH, Yoo NJ, Lee SH (2014) Regional bias of intratumoral genetic heterogeneity of nucleotide repeats in colon cancers with microsatellite instability. Pathol Oncol Res 20:965–971CrossRefPubMed
Metadaten
Titel
Intratumoral Heterogeneity of Somatic Mutations for NRIP1, DOK1, ULK1, ULK2, DLGAP3, PARD3 and PRKCI in Colon Cancers
verfasst von
Eun Ji Choi
Ju Hwa Lee
Min Sung Kim
Sang Yong Song
Nam Jin Yoo
Sug Hyung Lee
Publikationsdatum
26.08.2017
Verlag
Springer Netherlands
Erschienen in
Pathology & Oncology Research / Ausgabe 4/2018
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-017-0297-0

Weitere Artikel der Ausgabe 4/2018

Pathology & Oncology Research 4/2018 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.